Two CodeX HL7 FHIR Accelerator use case teams are hosting monthly public calls to involve a broad community in early prototype development and pilot planning activities currently underway.
- Join the CodeX Prior Authorization in Oncology team next on April 26 (3-4 ET) for an update on its radiation oncology pilot planning. Use case team members will display and discuss proposed workflow changes that can solve for treatment determination processes. Find the Zoom call information here.
- Join the CodeX REMS team next on April 29 (1-2 ET) to engage in a community discussion about REMS-related priorities, ideas, and suggestions. The team is looking for more voices to help lead the use case and pave the way to a real-world REMS solution—starting by investigating how the CodeX community can shape and pilot initial prototype work. Find registration information here under “Quick Links.”
- The CodeX HL7 FHIR Accelerator invites you to attend a free seminar focused on learning tools that make creating FHIR implementation guides easier. Course registration is available at: https://fshschool.org/courses/.
- The “FHIR Shorthand (FSH) Seminar: Getting Started with New Tools to Create Swimmingly Slick Implementation Guides” program will take place from May 24-26.
- This course is a comprehensive overview of FHIR IG authoring basics for people who are interested in being able to independently create FHIR IGs and help solve interoperability problems in the health industry.
- The course consists of:
- Asynchronous education materials paired with two days of LIVE support on Zulip and an
- Open Q&A FHIR Shorthand Forum
- Participants can expect to:Become familiar with the FHIR specification and commonly used FHIR resources and element types
- Learn the recommended process for successfully planning a new IG
- Gain proficiency with IG Authoring tools such as FSH, GoFSH, SUSHI
- Learn how to create the common components of an IG, including FHIR profiles, code systems, and value sets
- Learn about key FHIR profile concepts including value set binding, cardinality, MustSupport, slicing, and extensions.
Please reach out to Kim Ball, CodeX Deputy Program Manager (firstname.lastname@example.org) if you have questions or are interested in CodeX membership.
- CodeX Home page: https://confluence.hl7.org/display/COD/CodeX+Home
- CodeX Prior Authorization in Oncology home page: https://confluence.hl7.org/display/COD/Prior+Authorization+in+Oncology
- CodeX Risk Evaluation & Mitigation Strategies (REMS) home page: https://confluence.hl7.org/display/COD/Risk+Evaluation+and+Mitigation+Strategies+-+REMS
[i] Risk Evaluation and Mitigation Strategies (REMS) is a drug safety program that the FDA (Food and Drug Administration) can require for certain medications with potential for serious adverse side effects to help ensure the benefits of the medication outweigh its risks. REMS allows the prescribing of drugs that otherwise would not be available because of safety issues. Only a few drugs require REMS (currently 61 REMS exist). REMS required actions vary with each drug or drug class (e.g., opioid).